Serving the Society Since 1986
高级搜索
Volume 37 Issue 3
June 2022

    Minglong Liang, Zongmei Wang, Chuanjian Wu, Sidong Xiong, Ling Zhao and Chunsheng Dong. A single dose of recombinant VSV-RABVG vaccine provides full protection against RABV challenge[J]. Virologica Sinica, 2022, 37(3): 455-458. doi: 10.1016/j.virs.2022.02.008
    Citation: Minglong Liang, Zongmei Wang, Chuanjian Wu, Sidong Xiong, Ling Zhao, Chunsheng Dong. A single dose of recombinant VSV-RABVG vaccine provides full protection against RABV challenge .VIROLOGICA SINICA, 2022, 37(3) : 455-458.  http://dx.doi.org/10.1016/j.virs.2022.02.008
    shu

    单剂重组水泡性口炎病毒VSV-RABVG疫苗免疫对狂犬病毒RABV感染提供充分保护

    • a 生物医学研究院, 苏州大学 江苏 苏州 215123;

    • b 农业微生物国家重点实验室, 华中农业大学 湖北武汉 430070;

    • c 动物医学院湖北省预防兽医学重点实验室, 华中农业大学 湖北武汉 430070

    • 由狂犬病病毒（RABV）感染引起的狂犬病仍然是一个严重的全球公共卫生问题，每年造成6万多人死亡。市面上用于人的狂犬病疫苗是通过组织或者鸡鸭胚培养而来，灭活纯化的RABV颗粒。目前，无论是暴露前预防还是暴露后预防都需要多次接种灭活的RABV疫苗。重组水泡性口炎病毒（rVSV）被广泛用作疫苗平台。在本研究中，我们构建了RABV-G囊膜蛋白替换的rVSV并评估了免疫小鼠的抗原特异性体液免疫应答。我们证明单剂量VSV-RABVG鼻内免疫可诱导有效的抗原特异性体液免疫应答，尤其是免疫后4周诱导的病毒中和抗体。更为重要的是，免疫小鼠在受到致病性RABV株DRV-Mexico感染时，与RABV减毒株免疫小鼠（60%）相比，用VSV-RABVG免疫的小鼠100%得到充分保护。总之，我们的研究提供了一种有效且方便的基于VSV的疫苗，在防控狂犬病方面具有潜在的应用价值。

    A single dose of recombinant VSV-RABVG vaccine provides full protection against RABV challenge

    • a Jiangsu Key Laboratory of Infection and Immunity, Institutes of Biology and Medical Sciences, Soochow University, Suzhou 215123, China;

    • b State Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University, Wuhan 430070, China;

    • c Key Laboratory of Preventive Veterinary Medicine of Hubei Province, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430070, China

    • Highlights:
      1. A replication-competent recombinant VSV with RABV-G protein replacement was generated.
      2. Single dose of VSV-RABVG immunization induce potent antigen-specific humoral immune response, especially the virus neutralizing antibodies.
      3. Mice intranasally immunized with single dose of VSV-RABVG were 100% protected upon RABV challenge.
    • 加载中

      1. Bommier, E., Chapat, L., Guiot, A.L., Hilaire, F., Cariou, C., Poulet, H., Pialot, D., De Luca, K., 2020. Multivariate analysis of the immune response to different rabies vaccines. Vet. Immunol. Immunopathol. 220, 109986.

      2. China CDC, 2016. Technical guidelines for human rabies prevention and contro. https://www.chinacdc.cn/zxdt/201602/t20160201_125012.html (accessed on 20 June 2021).

      3. Douglas S, Lyles IVK, Rupprecht CE. 2013. Rhabdoviridae, p 885-922. In Knipe DM, Howley PM, Cohen JL, Griffin DE, Lamb RA, Martin MA, Racaniello VR, Roizman B (ed), Fields Virology, 6th ed, vol 1. Lippincott Williams and Wilkens, Philadelphia, PA

      4. Ertl, H.C.J., 2019. New rabies vaccines for use in humans. Vaccines (Basel) 7 (2), 54.

      5. Ge, J., Wang, X., Tao, L., Wen, Z., Feng, N., Yang, S., Xia, X., Yang, C., Chen, H., Bu, Z., 2011. Newcastle disease virus-vectored rabies vaccine is safe, highly immunogenic, and provides long-lasting protection in dogs and cats. J. Virol. 85, 8241-8252.

      6. Hampson, K., Coudeville, L., Lembo, T., Sambo, M., Kieffer, A., Attlan, M., Barrat, J., Blanton, J.D., Briggs, D.J., Cleaveland, S., Costa, P., Freuling, C.M., Hiby, E., Knopf, L., Leanes, F., Meslin, F.X., Metlin, A., Miranda, M.E., Muller, T., Nel, L.H., Recuenco, S., Rupprecht, C.E., Schumacher, C., Taylor, L., Vigilato, M.A., Zinsstag, J., Dushoff, J., Global Alliance for Rabies Control Partners for Rabies, P, 2015. Estimating the global burden of endemic canine rabies. PLoS Neglected Trop. Dis. 9, e0003709.

      7. Lawson, N.D., Stillman, E.A., Whitt, M.A., Rose, J.K., 1995. Recombinant vesicular stomatitis viruses from DNA. Proc. Natl. Acad. Sci. U. S. A. 92, 4477-4481.

      8. Lebrun, A., Garcia, S., Li, J., Kean, R.B., Hooper, D.C., 2017. Protection against CNStargeted rabies virus infection is dependent upon type-1 immune mechanisms induced by live-attenuated rabies vaccines. Tropical Med. Infect. Dis. 2, 22.

      9. Li, Y., Zhao, L., Sui, B., Luo, Z., Zhang, Y., Wang, Y., 2020. Recombinant rabies virus overexpressing OX40-ligand enhances humoral immune responses by increasing T follicular helper cells and germinal center B cells. Vaccines 8, 144.

      10. Park, J.E., Shin, H.J., 2021. Immunogenicity of replication-deficient vesicular stomatitis virus based rabies vaccine in mice. Vet. Q. 41, 202-209.

      11. Singh, R., Singh, K.P., Cherian, S., Saminathan, M., Kapoor, S., Manjunatha Reddy, G.B., Panda, S., Dhama, K., 2017. Rabies-epidemiology, pathogenesis, public health concerns and advances in diagnosis and control:a comprehensive review. Vet. Q. 37, 212-251.

      12. WHO, 2013. WHO Expert Consultation on Rabies. Second report. World Health Organ Tech Rep Ser, pp. 1-139. back cover.

      13. Wu, C., Wu, M., Liang, M., Xiong, S., Dong, C., 2019. A novel oncolytic virus engineered with PD-L1 scFv effectively inhibits tumor growth in a mouse model. Cell. Mol. Immunol. 16, 780-782.

      14. Wu, F., Fan, X., Yue, Y., Xiong, S., Dong, C., 2014. A vesicular stomatitis virus-based mucosal vaccine promotes dendritic cell maturation and elicits preferable immune response against coxsackievirus B3 induced viral myocarditis. Vaccine 32, 3917-3926.

      15. Yahalom-Ronen, Y., Tamir, H., Melamed, S., Politi, B., Shifman, O., Achdout, H., Vitner, E.B., Israeli, O., Milrot, E., Stein, D., Cohen-Gihon, I., Lazar, S., Gutman, H., Glinert, I., Cherry, L., Vagima, Y., Lazar, S., Weiss, S., Ben-Shmuel, A., Avraham, R., Puni, R., Lupu, E., Bar-David, E., Sittner, A., Erez, N., Zichel, R., Mamroud, E., Mazor, O., Levy, H., Laskar, O., Yitzhaki, S., Shapira, S.C., Zvi, A., Beth-Din, A., Paran, N., Israely, T., 2020. A single dose of recombinant VSV-G-spike vaccine provides protection against SARS-CoV-2 challenge. Nat. Commun. 11, 6402.

      16. Zhang, Y., Yang, J., Li, M., Cui, M., Fu, Z.F., Zhao, L., Zhou, M., 2019. A recombinant rabies virus expressing fms-like tyrosine kinase 3 ligand (Flt3L) induces enhanced immunogenicity in mice. Virol. Sin. 34, 662-672.

    • 加载中

    • Electronic Supplementary Material

      10.1016j.virs.2022.02.008-ESM.doc
    PDF

    Article Metrics

    Article views(5953) PDF downloads(37) Cited by(0)

    Related
    Proportional views
      通讯作者: 陈斌, bchen63@163.com
      • 1. 

        沈阳化工大学材料科学与工程学院 沈阳 110142

      1. 本站搜索
      2. 百度学术搜索
      3. 万方数据库搜索
      4. CNKI搜索

      A single dose of recombinant VSV-RABVG vaccine provides full protection against RABV challenge

        Corresponding author: Sidong Xiong, sdxiong@suda.edu.cn
        Corresponding author: Ling Zhao, zling604@yahoo.com
        Corresponding author: Chunsheng Dong, chunshengdong@suda.edu.cn
      • a Jiangsu Key Laboratory of Infection and Immunity, Institutes of Biology and Medical Sciences, Soochow University, Suzhou 215123, China;
      • b State Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University, Wuhan 430070, China;
      • c Key Laboratory of Preventive Veterinary Medicine of Hubei Province, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430070, China
      • Received Date: 20 July 2021
      • Accepted Date: 23 February 2022

      Abstract: Highlights:
      1. A replication-competent recombinant VSV with RABV-G protein replacement was generated.
      2. Single dose of VSV-RABVG immunization induce potent antigen-specific humoral immune response, especially the virus neutralizing antibodies.
      3. Mice intranasally immunized with single dose of VSV-RABVG were 100% protected upon RABV challenge.

        HTML

      Reference (16) Relative (20)

      目录

      鄂ICP备05001977号

         

      鄂公网安备 42010602003674号

      Copyright © 2019 Virologica Sinica. All rights reserved

      /

      DownLoad:  Full-Size Img  PowerPoint
      Return
      Return